Neuralink has announced it has enrolled 21 people in its human brain implant study as of this month, marking a new stage in testing devices designed to help people with paralysis control digital tools using neural signals. The announcement comes shortly after one of its earliest patients had publicly described the implant as life-changing.
Early results begin to draw attention
The company, founded in 2016 by Elon Musk, is developing implantable brain-computer interfaces intended to restore lost abilities such as communication and movement. Participants in the trial have used the system to move cursors, browse the web, and play simple games through thought-based control.
Enrollment has grown steadily from its initial 12 participants in September of last year, giving researchers more data on safety and device performance. Neuralink says no serious side effects linked to the implant have been reported so far, though long-term monitoring is ongoing.
The company’s first attempt to begin human testing was rejected by the US Food and Drug Administration in 2022 over concerns including battery safety and implant stability. After design revisions and additional safeguards, Neuralink received approval to launch trials in 2024.
In recent exclusive interview with Sky News, the first recipient of the implant described the experience as restoring a sense of independence, calling the early results “magical”.
Medical experts continue note that while initial outcomes may seem promising, broader conclusions will require larger trials and longer follow-up.
The race to give brains a computer
Neuralink is one of several companies working to commercialize brain-computer interface technology. Rivals including Synchron and Precision Neuroscience are advancing their own clinical programs, using different surgical methods and hardware designs.
Merge Labs, co-founded by OpenAI CEO Sam Altman, also recently raised $252 million to bring its own vision closer to reality, with a goal to create technology that can seamlessly fuse a brain with artificial intelligence – without surgery.
The field is drawing increased investment as researchers explore treatments for paralysis, spinal cord injury, and other neurological conditions. Regulators, however, continue to scrutinize safety standards closely, given the risks associated with implantable brain devices.
